Series A - Eliem Therapeutics
Investment Firm
Overview
Eliem Therapeutics is a clinical-stage biotechnology company developing treatments for nervous system disorders.
Announced Date
Mar 25, 2021
Funding Type
Series A
Highlights
Location
United States, North America
Social
Investor Lead
Access Biotechnology
Access Biotechnology is a early_stage_venture and late_stage_venture and post_ipo and seed and venture firm.
Intermediate Capital Group
Intermediate Capital Group is a debt and private_equity firm.
RA Capital Management
RA Capital Management is a convertible_note and debt and early_stage_venture and late_stage_venture and post_ipo and private_equity and seed and venture firm.
Participant Investors
3
Round Details and Background
Eliem Therapeutics raised $80000000 on 2021-03-25 in Series A
Eliem Therapeutics is a clinical-stage biotechnology company developing treatments for nervous system disorders.
Company Funding History
7
| Announcment Date | Transaction Name | Number Of Investors | Lead Investor | Money Raised |
|---|---|---|---|---|
| Mar 25, 2021 |  Series A - Eliem Therapeutics | 3 | - | 80.0M |
| May 24, 2021 | Series B - Eliem Therapeutics | 6 | - | 60.0M |
| Apr 11, 2024 | Post-IPO Equity - Eliem Therapeutics | 6 | - | 120.0M |
| Jun 27, 2024 | Post-IPO Equity - Eliem Therapeutics | 1 | - | 120.0M |
Recent Activity
There is no recent news or activity for this profile.